ESR1 and breast carcinoma: Furthermore, OSU-ERb-12 exhibited cytotoxicity toward the corresponding endocrine- and CDK4/6 inhibitor-resistant derivative lines of MCF7 and T47D with either similar or even significantly lower IC50 values, demonstrating its therapeutic efficacy toward both treatment-naïve and -resistant ERα+ breast cancer cells.